Yossef Av-Gay
Israeli | |
---|---|
Education | Tel Aviv University (BSc, MSc, PhD) |
Occupation(s) | University professor, adjunct professor, researcher, microbiologist |
Years active | 1980–present |
Medical career | |
Institutions | University of British Columbia, Canada Ben-Gurion University of the Negev, Israel |
Research | Microbiology |
Yossef Av-Gay (born 1961) is a Canadian
Education
Av-Gay received his BSc in Biology, MSc in Microbiology, and PhD in Microbial Genetics – all from
Research work
He became a microbiologist after education and training. Having been recognized for his research interests, which lies on diseases including chronic
Av-Gay's research is geared towards the identification and characterization of novel drugs and drug targets in Mycobacterium tuberculosis,[2] and COVID-19.[3]
His early works were characterized and identified
Av-Gay's most significant discovery was the identification and characterization of PtpA, a protein phosphatase in Mtb which inhibits the normal macrophage response to infection.[4]
Av-Gay authored over 100 peer review scientific publications, review articles, book chapters and 15 patents; he served as an editor for the
References
- ^ "Yossef Av-Gay | Infectious Diseases". UBC Canada.
- ^ "ATS: High-dose nitric oxide looks promising for infants with bronchiolitis". MDedge.
- PMID 36508083.
- PMID 22087003.
- PMID 24554699.
External links
- Yossef Av-Gay publications indexed by Google Scholar
- Patents by Inventor Yossef Av-Gay